… In this setting, combining erlotinib with chemotherapeutic agents may be necessary to
achieve … with erlotinib monotherapy,18, 21 two randomized, double-blind, placebo-controlled …

… in four randomized phase III trials. In these studies, concurrent administration of erlotinib or
… or both; although the presentation of the rash produced by these two agents is different, no …

… -agent erlotinib has been proved by phase I/II studies in previously treated patients 10 . In a
large randomized, double-blind, placebo-controlled phase … of nine randomized phase II or III …

… -agent erlotinib. Follow-up for survival continued until 31 March 2011. Three patients
continued on treatment after this date (two in the figitumumab arm and one in the control arm) and …

… Erlotinib treatment as a single agent has been evaluated in advanced NSCLC patients
after … in a large (731 patients), multicenter randomized phase III clinical trial (BR21 study) in …

… To the best of our knowledge, no studies comparing docetaxel or pemetrexed and intermitted
erlotinib with single-agent erlotinib in second-line treatment of NSCLC are available in the …

… Patients developing toxicity with paclitaxel and/or carboplatin had the option to continue one
of the chemotherapy agents alone along with erlotinib or with erlotinib alone. Management …

… Erlotinib has insufficient single-agent activity in unselected … In a phase I study of erlotinib
with or without TMZ, in which 57 … responding patients had only received erlotinib. In that study, …

… agents has been explored, but no current phase III data show superiority of an approach
combining an EGFR inhibitor with a second agent [… Recent results from randomized prospective …

… for erlotinib, which extended to the subgroup of patients with PS 2 and 3. On the basis of these
observations, we conducted a randomized phase … agents in the treatment of PS 2 patients. …